Artin's COPD therapy is expected to be effective for Severe Asthma. Our strategy is at the time we receive regulatory approval for COPD we will immediately apply for approval for a Severe Asthma trial arm.

​

Our intention is to use the identical drug therapy for Severe Asthma as we do for COPD. 

 

Severe asthma is a chronic respiratory condition characterized by persistent, uncontrolled asthma symptoms despite high-dose inhaled corticosteroids and additional controller medications (e.g., long-acting beta-agonists). It involves frequent or severe asthma attacks, significant airflow limitation, and symptoms like wheezing, shortness of breath, chest tightness, or coughing that impair daily life.

 

Standard treatments include ICS, LABA, OCS, and LTRAs. Patients with severe asthma who do not respond are prescribed monoclonal antibodies (mAbs).

​

mAbs targeting specific immune pathways have significantly improved asthma control in non-responders to standard treatments, reducing exacerbations and enhancing lung function.

​

Despite their efficacy, it is estimated that 40-50% of patients on mAbs still do not respond to treatment (due to phenotype).

​

Standard Asthma therapies are easily administered orally or by inhalation, while mAbs require more cumbersome SC injections or IV infusions every 2-8 weeks. Additionally, mAbs are significantly more expensive, costing $10,000-$40,000 annually compared to standard treatments.

​

Beyond treating inflammation, Artin’s treatment combining classical and new innovative approaches aims to:

• Arrest oxidative stress;

• Protect endothelial cells;

• Improve gas exchange;

• Treat bronchoconstriction;

• Arrest structural change in the lung;

• Targets eosinophils.

​

Artin’s multi-factorial approach is expected to be promising in expanding the population that responds to treatment with the following advantages:

​

1. Convenient administration for systemic and local action via oral and inhaled delivery.​

2. A more affordable, economic new therapy to improve severe asthma management.

3. ​​Nonsteroidal, non mAb, systemic treatment, dramatically decreases the supply of inflammatory cells, which cause chronicity and flare-ups.

​​

​

The following illustrates the scientific rational for applying the COPD therapy to Severe Asthma